Multi-omics Analysis of Women With PCOS and Obesity Compared With Non-PCOS Obese Controls
- Conditions
- Polycystic Ovary Syndrome
- Interventions
- Other: No intervention
- Registration Number
- NCT05468476
- Lead Sponsor
- Zhang Manna
- Brief Summary
Polycystic ovary syndrome (PCOS) is a common endocrine and metabolic disorder in reproductive-aged women， which associated with increased risks to develop metabolic disorders, including cardiovascular diseases, diabetes mellitus, and cerebrovascular diseases. The precise pathogenesis of PCOS remains unknown but is thought to be multifactorial, comprising genetic and environmental factors .
- Detailed Description
To study the pathogenesis of diseases, the study of multi-omics approach has been applied in various diseases researching . Obesity and PCOS are both metabolic disorders, and both have an impact on metagenomics, metabolomics and transcriptome. Currently, multi-omics studies based on obese PCOS are still limited. Therefore, this study tried to use a multi-omics approach that integrates the gut microbiome, serum metabolomics, serum transcriptomics, and clinical indicators to distinguish obese PCOS from obese non-PCOS women. To investigate whether the specific composition of the gut microbiome is associated with PCOS in obese women. Serum metabolomics and transcriptomics were analyzed to explore potential metabolic pathways. Meanwhile, gut microbiome and serum metabolomics are used to predict the occurrence of PCOS. Then, a new metabolite that could predict PCOS were tested on female mice with high fat diet (HFD).
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 121
- patients with obesity (BMI>28kg/m2)
- aged 18-45 years
- Diagnosis of PCOS
- the Rotterdam diagnosis criteria (2003)
- Pregnant women;
- Hyperthyroidism or hypothyroidism
- Severe liver and kidney function injury
- Cancer patients;
- Associated with severe infection, severe anemia, neutropenia and other blood system diseases;
- Have type 1 diabetes, single-gene mutated diabetes or other secondary diabetes;
- Patients with mental illness or intellectual disability;
- Have taken drugs for PCOS treatment in the last three months;
- Taking drugs or foods (antibiotics, probiotics, yogurt, etc.) that affect the intestinal flora for nearly one month;
- Have a long history of taking hormone therapy;
- Currently or recently participating in another clinical trial.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Women with PCOS (PCOS group) No intervention PCOS women with obesity previously diagnosed with PCOS（meet the 2003 Rotterdam diagnostic criteria） not using hormonal therapy and without other significant health or endocrine issues. Women without PCOS (Non-PCOS group) No intervention This study enrolled age- and body mass index (BMI)-matched subjects with normal menstrual cycles, not using hormonal therapy, and without any significant health or endocrine issues.
- Primary Outcome Measures
Name Time Method Phenotype differences in the Serum non-targeted metabolomics by LC-MS. Samples to be collected once per participant within 7 days of enrollment. Understand phenotypical differences from biological samples comparing women with and without PCOS. Venipuncture blood draws are to be completed and analyzed by a commercial laboratory to comprehensively analyze non-target metabolites.
Phenotype differences in the gut microbiome by metagenomic sequencing. Samples to be collected once per participant within 7 days of enrollment Understand phenotypical differences from biological samples comparing women with and without PCOS. Stool samples are to be collected by women and analyzed with metagenomics sequencing.
Phenotype differences in the transcriptome expression by mRNA-seq. Samples to be collected once per participant within 7 days of enrollment. Understand phenotypical differences from biological samples comparing women with and without PCOS. The researcher will collect and analyze Venipuncture blood for RNA. Differences in the expression of genes between the two groups of subjects, analysis to select possible pathogenic factors leading to the pathogenesis of PCOS.
Phenotype differences in the Serum targeted metabolomics by LC-MS. Samples to be collected once per participant within 7 days of enrollment. Understand phenotypical differences from biological samples comparing women with and without PCOS. Venipuncture blood draws are to be completed and analyzed by a commercial laboratory to comprehensively analyze the target metabolite.
- Secondary Outcome Measures
Name Time Method BMI Samples to be collected once per participant within 7 days of enrollment. Body mass index (BMI)=weight(kg)/height(m)\^2.
E2 Samples to be collected once per participant within 7 days of enrollment. Estradiol in pmol/L.
PRL Samples to be collected once per participant within 7 days of enrollment. Prolactin in uIU/ml.
HC Samples to be collected once per participant within 7 days of enrollment. Hip Circumference in centimeters.
WC Samples to be collected once per participant within 7 days of enrollment. Waist Circumference in centimeters.
Waist/hip Ratio Samples to be collected once per participant within 7 days of enrollment. WHR=(Waist Circumference in centimeters)/(Hip Circumference in centimeters).
FBG Samples to be collected once per participant within 7 days of enrollment. fasting blood-glucose in mmol/L.
TT Samples to be collected once per participant within 7 days of enrollment. total testosterone in nmol/L.
LH Samples to be collected once per participant within 7 days of enrollment. luteinizing hormone in IU/L.
FSH Samples to be collected once per participant within 7 days of enrollment. The follicle-stimulating hormone in IU/l.
Menstrual cycles Samples to be collected once per participant within 7 days of enrollment. the total number of menstrual periods in the last year.
ALT Samples to be collected once per participant within 7 days of enrollment. alanine aminotransferase in U/L.
UA Samples to be collected once per participant within 7 days of enrollment. Uric acid in umol/L.
PBG Samples to be collected once per participant within 7 days of enrollment. postprandial blood-glucose in mmol/L.
FINS Samples to be collected once per participant within 7 days of enrollment. fasting serum insulin in mU/L.
PINS Samples to be collected once per participant within 7 days of enrollment. postprandial insulin in mU/L.
AST Samples to be collected once per participant within 7 days of enrollment. aspartate aminotransferase in U/L.
CR Samples to be collected once per participant within 7 days of enrollment. Creatinine in umol/L.
Ferriman-Gallwey score Samples to be collected once per participant within 7 days of enrollment. The minimum value of Ferriman-Gallwey score is 0 and the maximum value is 44. An Ferriman-Gallwey score greater than or equal to 6 is considered to be a clinical manifestation of androgen excess.
HOMA-IR Samples to be collected once per participant within 7 days of enrollment. Homeostatic model assessment insulin resistance index=FBG\*FINS/22.5.
HbA1c (%) Samples to be collected once per participant within 7 days of enrollment. glycosylated hemoglobin (%).
γ-GT Samples to be collected once per participant within 7 days of enrollment. γ-glutamyl transferase in U/L.
BUN Samples to be collected once per participant within 7 days of enrollment. urea nitrogen in mmol/L.
SOD Samples to be collected once per participant within 7 days of enrollment. Superoxide dismutase in pg/ml.
Interleukin 22, IL-22 Samples to be collected once per participant within 7 days of enrollment. Interleukin 22 in pg/ml. The factor reflects that the organism is in an inflammatory state. There is no maximum or minimum value for the factor and the higher scores mean a worse outcome.
Interleukin 6，IL-6 Blood samples to be collected once per participant within 7 days of enrollment. Interleukin 6 in pg/ml. The factor reflects that the organism is in an inflammatory state. There is no maximum or minimum value for the factor and the higher scores mean a worse outcome.
Interleukin 8， IL-8 Blood samples to be collected once per participant within 7 days of enrollment. Interleukin 8 in pg/ml. The factor reflects that the organism is in an inflammatory state. There is no maximum or minimum value for the factor and the higher scores mean a worse outcome.
AD Blood samples to be collected once per participant within 7 days of enrollment. Androstenedione in ng/ml.
LDL-c Blood samples to be collected once per participant within 7 days of enrollment. low-density lipoprotein cholesterol in mmol/L.
HDL-c Blood samples to be collected once per participant within 7 days of enrollment. high-density lipoprotein cholesterol in mmol/L.
Tumor Necrosis Factor， TNF Blood samples to be collected once per participant within 7 days of enrollment. Tumor Necrosis Factor in pg/ml. The factor reflects that the organism is in an inflammatory state. There is no maximum or minimum value for the factor and the higher scores mean a worse outcome.
FT Blood samples to be collected once per participant within 7 days of enrollment. free testosterone in nmol/L.
DHEAS Blood samples to be collected once per participant within 7 days of enrollment. Dehydroepiandrosterone Sulfate in ug/dl.
SHBG Blood samples to be collected once per participant within 7 days of enrollment. sex hormone-binding globulin in nmol/L.
TC Blood samples to be collected once per participant within 7 days of enrollment. Total Cholesterol in mmol/L.
TG Blood samples to be collected once per participant within 7 days of enrollment. Triglyceride in mmol/L.
CRP Blood samples to be collected once per participant within 7 days of enrollment. C reactive protein in pg/ml.
Trial Locations
- Locations (1)
Department of Endocrinology, Shanghai Tenth People's Hospital
🇨🇳Shanghai, Shanghai, China